Repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression in Parkinson disease: a meta-analysis of randomized controlled clinical trials

Neurological Sciences

Volumn 36, Issue 10, 2015, Pages 1751-1761

  Xie, Cheng Long ^a,b   Chen, Jie ^a   Wang, Xiao Dan ^c   Pan, Jia Lin ^a   Zhou, Yi ^a   Lin, Shi Yi ^a   Xue, Xiao Dong ^d   Wang, Wen Wen ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d Cang Nan County Hospital   (China)

Author keywords

Depression; Meta analysis; Parkinson s disease; Repetitive transcranial magnetic stimulation; rTMS; Systematic review

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

DEPRESSION; DSM-IV; HUMAN; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOTOR PERFORMANCE; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; DEPRESSIVE DISORDER; PROCEDURES;

DEPRESSIVE DISORDER; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84942502372     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-015-2345-4     Document Type: Review

References (33)

1. Reijnders JS, Ehrt U, Weber WE et al (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23(2):183–189
2. Nilsson FM, Kessing LV, Sørensen TM et al (2002) Major depressive disorder in Parkinson’s disease: a register-based study. Acta Psychiatr Scand 106(3):202–211
3. Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 69(3):308–312
4. Skapinakis P, Bakola E, Salanti G et al (2010) Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol 10:49
5. Rektorová I, Rektor I, Bares M et al (2003) Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol 10(4):399–406
6. Ridding MC, Rothwell JC (2007) Is there a future for therapeutic use of transcranial magnetic stimulation? Nat Rev Neurosci 8(7):559–567
7. Pascual-Leone A, Valls-Solé J, Wassermann EM et al (1994) Responses to rapid-rate transcranial magnetic stimulation of the human motor cortex. Brain 117:847–858
8. Pal E, Nagy F, Aschermann Z et al (2010) The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Mov Disord 25(14):2311–2317
9. Fregni F, Santos CM, Myczkowski ML et al (2004) Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 75(8):1171–1174
10. O’Reardon JP, Solvason HB, Janicak PG et al (2007) Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 62(11):1208–1216
11. Higgins JP, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
12. Vesterinen HM, Sena ES, Egan KJ et al (2014) Meta-analysis of data from animal studies: a practical guide. J Neurosci Methods 221:92–102
13. Boggio PS, Fregni F, Bermpohl F et al (2005) Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson’s disease and concurrent depression. Mov Disord 20(9):1178–1184
14. Cardoso EF, Fregni F, Martins Maia F et al (2008) rTMS treatment for depression in Parkinson’s disease increases BOLD responses in the left prefrontal cortex. Int J Neuropsychopharmacol 11(2):173–183
15. Chen SD, Yu SW, Zhao JF et al (2011) The effect of rTMS treatment for depression in Parkinson’s disease. Chin J Gerontol 31:3482–3484
16. Feng JM, Li SM, Guo W, et al (2012) Research of optimize rTMS treatment for depression in Parkinson’s disease. HaiNan Med 23(16):35–38
17. Niu XP, Gou YC (2012) Observation of rTMS treatment for depression in Parkinson’s disease. Chin J Prac Nurs 15(16):11–13
18. Wu ZH, Cen HH, Cui LQ et al (2013) Efficacy Studies of High and Low Frequency Repetitive Transcranial Magnetic Stimulation Joint Sertraline in the Treatment of Parkinson’s Disease Patients with Depression. Mod Diagn Treat 24(10):2164–2167
19. Wassermann EM, Grafman J, Berry C et al (1996) Use and safety of a new repetitive transcranial magnetic stimulator. Electroencephalogr Clin Neurophysiol 101(5):412–417
20. Tollefson GD, Bosomworth JC, Heiligenstein JH et al (1995) A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. Int Psychogeriatr 7(1):89–104
21. Pascual-Leone A, Rubio B, Pallardó F et al (1996) Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 348(9022):233–237
22. Siebner HR, Lang N, Rizzo V et al (2004) Preconditioning of low-frequency repetitive transcranial magnetic stimulation with transcranial direct current stimulation: evidence for homeostatic plasticity in the human motor cortex. J Neurosci 24(13):3379–3385
23. Elahi B, Elahi B, Chen R (2009) Effect of transcranial magnetic stimulation on Parkinson motor function–systematic review of controlled clinical trials. Mov Disord 24(3):357–363
24. Klein E, Kreinin I, Chistyakov A et al (1999) Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. Arch Gen Psychiatry 56(4):315–320
25. Post A, Müller MB, Engelmann M et al (1999) Repetitive transcranial magnetic stimulation in rats: evidence for a neuroprotective effect in vitro and in vivo. Eur J Neurosci 11(9):3247–3254
26. Keck ME, Welt T, Müller MB et al (2002) Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system. Neuropharmacology 43(1):101–109
27. Padberg F, Möller HJ (2003) Repetitive transcranial magnetic stimulation: does it have potential in the treatment of depression? CNS Drugs. 17(6):383–403
28. Chen R (2010) Repetitive transcranial magnetic stimulation as treatment for depression in Parkinson’s disease. Mov Disord 25(14):2272–2273
29. Thorlund K, Imberger G, Walsh M et al (2011) The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis—a simulation study. PLoS One 6(10):e25491
30. Rosenthal R, DiMatteo MR (2001) Meta-analysis: recent developments in quantitative methods for literature reviews. Annu Rev Psychol 52:59–82
31. Guyatt GH, Oxman AD, Montori V et al (2011) GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol 64(12):1277–1282
32. Davidson RJ, Abercrombie H, Nitschke JB et al (1999) Regional brain function, emotion and disorders of emotion. Curr Opin Neurobiol 9(2):228–234
33. Chen Y, Guo JJ, Zhan S et al (2006) Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother 40(12):2115–2122